XWELL, Inc.
$1.2
▼
-7.76%
2026-04-21 10:23:00
www.xwell.com
NCM: XWEL
Explore XWELL, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.7 M
Current Price
$1.2
52W High / Low
$2.2 / $0.26
Stock P/E
—
Book Value
$-1.1
Dividend Yield
—
ROCE
-75.03%
ROE
-275.96%
Face Value
—
EPS
$-5.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
175
Beta
0.96
Debt / Equity
-13.66
Current Ratio
0.46
Quick Ratio
0.42
Forward P/E
-0.45
Price / Sales
0.32
Enterprise Value
$28.98 M
EV / EBITDA
-3.41
EV / Revenue
0.99
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Medpace Holdings, Inc. | $513.23 | 33.75 | $14.67 B | — | 84.68% | 70.23% | $628.92 / $250.05 | $16.18 |
| 2. | Natera, Inc. | $206.53 | — | $29.47 B | — | -15.84% | -14.32% | $256.36 / $131.81 | $12.26 |
| 3. | Thermo Fisher Scientific Inc. | $521.21 | 29.42 | $194.29 B | 0.36% | 8.52% | 13.02% | $643.99 / $385.46 | $141.96 |
| 4. | Mettler-Toledo International Inc. | $1,328.56 | 31.6 | $26.93 B | — | 44.48% | -1154.87% | $1,525.17 / $962.54 | $-1.16 |
| 5. | BillionToOne, Inc. | $86.97 | 489.81 | $3.65 B | — | 2.74% | 2.3% | $138.7 / $61.96 | $10.48 |
| 6. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 7. | OPKO Health, Inc. | $1.22 | — | $926.06 M | — | -12.27% | -17.14% | $1.6 / $1.09 | $1.67 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 7.15 M | 7.34 M | 7.69 M | 7.02 M | 7.47 M | — |
| Operating Profit | -3.22 M | -0.28 M | -2.69 M | -3.16 M | -3.88 M | — |
| Net Profit | -9.28 M | -0.72 M | -2.27 M | -4.72 M | -7.59 M | — |
| EPS in Rs | -1.17 | -0.09 | -0.29 | -0.6 | -0.96 | -0.99 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 29.21 M | 33.9 M | 30.11 M | 55.94 M |
| Operating Profit | -9.36 M | -12.1 M | -19.3 M | -24.55 M |
| Net Profit | -16.99 M | -16.85 M | -27.74 M | -32.84 M |
| EPS in Rs | -2.14 | -2.13 | -3.5 | -4.14 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.22 M | 25.35 M | 38.99 M | 70.43 M |
| Total Liabilities | 23.8 M | 17.61 M | 18.02 M | 22.48 M |
| Equity | -22.04 M | -0.79 M | 13 M | 39.93 M |
| Current Assets | 5.91 M | 15.34 M | 26.57 M | 47.33 M |
| Current Liabilities | 12.89 M | 9.22 M | 9.33 M | 10.96 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.71 M | -11.01 M | -16.07 M | -24.19 M |
| Investing CF | 4.33 M | 5.89 M | 5.65 M | -34.84 M |
| Financing CF | 1.94 M | 1.36 M | 0.01 M | -27.38 M |
| Free CF | -11.68 M | -12.8 M | -18.45 M | -31.02 M |
| Capex | -2.96 M | -1.79 M | -2.37 M | -6.84 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 12.58% | -46.18% | — | — |
| Earnings Growth % | 39.25% | 15.52% | — | — |
| Profit Margin % | -49.72% | -92.14% | -58.7% | — |
| Operating Margin % | -35.7% | -64.08% | -43.89% | — |
| Gross Margin % | 26.31% | 12.23% | 21.54% | — |
| EBITDA Margin % | -41.27% | -52.31% | -30.89% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-09-28 | 1:0.05 |